Hantz Financial Services, Inc. Rhythm Pharmaceuticals, Inc. Transaction History

Hantz Financial Services, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Aug 06, 2024	SELL	$4.3 - $30.85 $95,335 - $683,975	-22,171 Reduced 99.48%	115 $3,000
Q2 2022 Aug 06, 2024	BUY	$3.12 - $12.25 $7,484 - $29,387	2,399 Added 12.06%	22,286 $92,000
Q1 2022 Aug 06, 2024	BUY	$6.13 - $12.24 $18,500 - $36,940	3,018 Added 17.89%	19,887 $229,000
Q4 2021 Aug 06, 2024	BUY	$8.62 - $13.9 $94,699 - $152,705	10,986 Added 186.74%	16,869 $168,000
Q3 2021 Aug 06, 2024	BUY	$11.68 - $20.72 $68,713 - $121,895	5,883 New	5,883 $77,000

192

67.3M

834K

78.6K

Ticker RYTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,720,000
Market Cap $3.34B
Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...

Get notified when there are updates to the investment portfolio of Hantz Financial Services, Inc., based on Form 13F filings with the SEC.

Stay updated on Hantz Financial Services, Inc. with notifications on news.